Stern – who left B-M, where she launched AstraZeneca’s anti-cholesterol drug Crestor in the UK, last year – will join on 1 November in a four-days-a-week role, reporting to UK managing director Jennie Talman.
Stern joined B-M – where she worked briefly alongside Talman – as a senior account executive in 1996 and rose through the ranks to become UK healthcare MD, heading the agency’s work for AZ.
CCA has a client list that includes AZ, Novartis, Pfizer and Belgian company UCB Pharma.
Stern left B-M in August 2003 to go on maternity leave. She has spent the past few months doing freelance PR for a variety of organisations. While at B-M, in addition to promoting Crestor, Stern also promoted AZ’s prostate-cancer brand Casodex and pre-launch drugs within AZ’s ‘pain franchise’.
Before B-M, Stern spent 15 months at healthcare PR firm Interaction PR and Marketing. Prior to that she worked in the not-for-profit sector for organisations such as the British Youth Council and the World Council of Churches.
B-M lost the account for Crestor, which launched in the UK in March 2003, earlier this year to Red Door Communications (PRWeek, 6 February).
The agency was subsequently hit by the defection of UK healthcare practice chair and 15-year agency stalwart Kate Triggs, who quit to join Edelman.
B-M’s healthcare practice is being managed by director Richard Rockliffe and healthcare MD Amie Malkin as UK chief executive Per Heggenes continues his search for Triggs’s successor.